XRN Q3 2026 Same-Property Cash NOI Growth (Outpatient Medical) +1.6%, Beat Guidance by +0.1 pts
XRN beat prior Q3 2026 Same-Property Cash NOI Growth (Outpatient Medical) guidance by +0.1 pts. Same-Property Cash NOI Growth (Outpatient Medical) was maintained by 0.0 pts to 1.0%-2.0% (midpoint 1.5%). The company reported a net loss attributable to common stockholders of $8.9 million ($0.67 per share) compared to a net loss of $6.0 million ($0.45 per share) in Q3 2025, while FFO per share declined to $0.50 from $1.00 and Core FFO per share fell to $0.75 from $1.12. Total revenue increased 8.3% year-over-year t...
Read source-backed brief